GEN-001 / Genocea - LARVOL DELTA

Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer (clinicaltrials.gov) - P=N/A; N=40; Not yet recruiting; Sponsor: Korean Cancer Study Group

Clinical • New trial • Colorectal Cancer • Gastrointestinal Cancer • Immune Modulation • Immunology • Inflammation • Oncology • Rectal Cancer • Solid Tumor • CD4 • CD8

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy (clinicaltrials.gov) - P1; N=93; Recruiting; Sponsor: Genome & Company

Clinical • Combination therapy • New P1 trial • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer

"#GenomeCompany's #IimmunoAntiCancerMicrobiome treatment #GEN001 clinically approved by the Ministry of Food and Drug Safety https://t.co/ppiEhcEwEZ" (@1stOncology)

Clinical • Oncology

Genocea Announces Private Placement Financing of Up to $80 Million (GlobeNewswire) - "Genocea intends to use the net proceeds from this private placement to fund continued clinical and program development of its neoantigen vaccine GEN-009 and its neoantigen cell therapy GEN-011, as well as for working capital and other general corporate purposes."

Financing • Oncology